aid: breezebio accessModel: pricing: unknown onboarding: unknown trial: false try_now: false public: false label: Unknown confidence: low source: [] generated: '2026-07-22' method: derived image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/breezebio.png name: Breezebio description: >- BreezeBio (formerly GenEdit) is a South San Francisco genetic-medicine company developing precision-delivered nucleic acid therapies for autoimmune disease and oncology. Its proprietary NanoGalaxy platform uses non-lipid, hydrophilic polymer nanoparticles of tunable size, charge, and composition to selectively deliver DNA, RNA, and ribonucleoprotein payloads to specific tissues and cell types beyond the liver — including immune cells and targets in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline led by BRZ-101, which aims to restore immune tolerance in type 1 diabetes, and in February 2026 closed a $60M Series B backed by DCVC Bio, Sequoia Capital, and other investors. BreezeBio is a research-stage biopharmaceutical company and does not currently publish a public developer API, SDKs, or API documentation; this profile tracks its corporate and identity surface within the API Evangelist network. url: https://raw.githubusercontent.com/api-evangelist/breezebio/refs/heads/main/apis.yml x-type: company x-source: vc-portfolio x-backed-by: - dcvc - sequoia-capital x-tier: stub x-tier-reason: portfolio-lead specificationVersion: '0.20' created: '2026-07-17' modified: '2026-07-18' tags: - Company - Biotechnology - Genetic Medicine - Drug Delivery - Therapeutics - Life Sciences - Nanoparticles - Healthcare apis: [] common: - type: Website url: https://breezebio.com/ - type: Blog url: https://breezebio.com/news/ - type: Support url: https://breezebio.com/contact/ - type: PrivacyPolicy url: https://breezebio.com/legal/privacy-policy/ - type: TermsOfService url: https://breezebio.com/legal/terms-of-use/ maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io x-enrichment: date: '2026-07-19' status: backfilled pass: local-v1 note: backfilled from .gitignore signal + verified work evidence